Jessica Bogach1, Frances C Wright2,3, Janice Austin4, Stephanie Y Cheng5, Christina Diong5, Rinku Sutradhar5,6, Nancy N Baxter7,8,9,10, Nicole J Look Hong2,3. 1. Department of Surgery, University of Toronto, Toronto, ON, Canada. jessica.bogach@one-mail.on.ca. 2. Department of Surgery, University of Toronto, Toronto, ON, Canada. 3. Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 4. Department of Surgery, Joseph Brant Hospital, McMaster University, Hamilton, ON, Canada. 5. ICES, Toronto, ON, Canada. 6. Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. 7. Cancer Research Program, ICES, Toronto, ON, Canada. 8. Institute for Health Policy, Evaluation and Management, University of Toronto, Toronto, ON, Canada. 9. Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada. 10. Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.
Abstract
BACKGROUND: Melanoma and the immune system are intimately related. However, the association of immunosuppressive medications (ISMs) with survival in melanoma is not well understood. The study evaluated this at a population level. METHODS: A cohort of patients with a diagnosis of invasive cutaneous melanoma (2007-2015) was identified from the Ontario Cancer Registry and linked to identify demographics, stage at diagnosis, prescription of immunosuppressive medications (both before and after diagnosis), and outcomes. The demographics of patients with and without prescriptions for ISM were compared. Patients eligible for Ontario's Drug Benefit Plan were included to ensure accurate prescription data. The primary outcome was overall survival. Cox Proportional Hazards Regression models identified factors associated with mortality, including use of ISM as a time-varying covariate. RESULTS: Of the 4954 patients with a diagnosis of cutaneous melanoma, 1601 had a prescription for ISM. The median age of the patients was 74 years. Overall, 58.4% of the patients were men (60.5% of those without ISM and 54% of those using ISM; p < 0.001). The use of oral immunosuppression was associated with an increased hazard of death (hazard ratio, 5.84; 95% confidence interval, 5.11-6.67; p < 0.0001) when control was used for age, disease stage at diagnosis, anatomic site, comorbidity, and treatment. Other factors associated with death were increasing age, male sex, increased disease stage, truncal location of primary melanoma, and inadequate treatment. In sensitivity analysis with steroid-only ISM use excluded, survival did not differ significantly (p = 0.355). CONCLUSIONS: The use of immunosuppressive steroids for melanoma is associated with worse overall survival. Use of steroids should be limited when possible.
BACKGROUND:Melanoma and the immune system are intimately related. However, the association of immunosuppressive medications (ISMs) with survival in melanoma is not well understood. The study evaluated this at a population level. METHODS: A cohort of patients with a diagnosis of invasive cutaneous melanoma (2007-2015) was identified from the Ontario Cancer Registry and linked to identify demographics, stage at diagnosis, prescription of immunosuppressive medications (both before and after diagnosis), and outcomes. The demographics of patients with and without prescriptions for ISM were compared. Patients eligible for Ontario's Drug Benefit Plan were included to ensure accurate prescription data. The primary outcome was overall survival. Cox Proportional Hazards Regression models identified factors associated with mortality, including use of ISM as a time-varying covariate. RESULTS: Of the 4954 patients with a diagnosis of cutaneous melanoma, 1601 had a prescription for ISM. The median age of the patients was 74 years. Overall, 58.4% of the patients were men (60.5% of those without ISM and 54% of those using ISM; p < 0.001). The use of oral immunosuppression was associated with an increased hazard of death (hazard ratio, 5.84; 95% confidence interval, 5.11-6.67; p < 0.0001) when control was used for age, disease stage at diagnosis, anatomic site, comorbidity, and treatment. Other factors associated with death were increasing age, male sex, increased disease stage, truncal location of primary melanoma, and inadequate treatment. In sensitivity analysis with steroid-only ISM use excluded, survival did not differ significantly (p = 0.355). CONCLUSIONS: The use of immunosuppressive steroids for melanoma is associated with worse overall survival. Use of steroids should be limited when possible.
Authors: Alexander M M Eggermont; Christian U Blank; Mario Mandala; Georgina V Long; Victoria Atkinson; Stéphane Dalle; Andrew Haydon; Mikhail Lichinitser; Adnan Khattak; Matteo S Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A Ascierto; Piotr Rutkowski; Dirk Schadendorf; Rutger Koornstra; Leonel Hernandez-Aya; Michele Maio; Alfonsus J M van den Eertwegh; Jean-Jacques Grob; Ralf Gutzmer; Rahima Jamal; Paul Lorigan; Nageatte Ibrahim; Sandrine Marreaud; Alexander C J van Akkooi; Stefan Suciu; Caroline Robert Journal: N Engl J Med Date: 2018-04-15 Impact factor: 91.245
Authors: Jacob Schachter; Antoni Ribas; Georgina V Long; Ana Arance; Jean-Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian Blank; Teresa M Petrella; Omid Hamid; Honghong Zhou; Scot Ebbinghaus; Nageatte Ibrahim; Caroline Robert Journal: Lancet Date: 2017-08-16 Impact factor: 79.321
Authors: Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett Journal: Cancer Biol Ther Date: 2017-05-17 Impact factor: 4.742
Authors: Martin D McCarter; Joel Baumgartner; Guillermo A Escobar; Donald Richter; Karl Lewis; William Robinson; Cara Wilson; Brent E Palmer; Rene Gonzalez Journal: Ann Surg Oncol Date: 2007-06-26 Impact factor: 5.344
Authors: Richard J B Walker; Nicole J Look Hong; Marc Moncrieff; Alexander C J van Akkooi; Evan Jost; Carolyn Nessim; Winan J van Houdt; Emma H A Stahlie; Chanhee Seo; May Lynn Quan; J Gregory McKinnon; Frances C Wright; Michail N Mavros Journal: Ann Surg Oncol Date: 2022-06-08 Impact factor: 4.339